Webinars
Available On Demand
How has COVID-19 impacted launch performance and timing?
Pharmaceutical leaders are facing some of the toughest challenges of their careers when it comes to launching in the midst of COVID-19. With so much at stake and so much uncertainty, companies are looking for fact-based insights to power their decision-making.
Trinity has done an in-depth evaluation of the impact of COVID-19 on launch performance and timing. We have compared forecasted/expected revenue to actual revenue for products that launched within six months…
Watch Now
Blog
Published October 15, 2020
Written by Tom Rutkowski, Jay Galli, and Kate Watkins…
Read Now
Case Studies
Trinity organized a full day on-site workshop to bring together key cross functional client teams to align on a final launch strategy for their mNSCLC asset in Japan.
Geographic Scope:
Client Situation:
The client wanted to build alignment on the launch pricing & market access assumptions for their asset in metastatic non-small cell lung cancer (mNSCLC) and metastatic colorectal cancer (mCRC) in Japan, including consideration of all forecasting assumptions and pricing and market access (P&MA) risks.
Trinity’s Solution:
Trinity conducted targeted secondary research to determine the existing mNSCLC…
Read Now
Briefs
While COVID-19 is grinding world economies to a potentially disastrous halt, the pharmaceutical and biotech industry continues to move forward at a slower pace.
How can companies ensure an agile launch despite the uncertainty and ensure launch success during and in a post-COVID-19 world?
Publication Access Form…
Read Now
White Papers
2018 and 2019 were banner years for approvals with over 50 drugs approved by the FDA and the EMA each year. 2020 looks no different. As you prepare for your unique launch in an ever-changing landscape, we understand the challenges you may face: limited resources, lack of prioritization, misalignment, diversity of markets. Based on Trinity’s experience supporting dozens of launches in 2019 alone and through a landmark research study with 30 Chief Commercial Officers (CCOs) who had recently launched a product, we…
Read Now
White Papers
The annual Trinity Drug Index provides a comprehensive evaluation of the performance of drugs by therapeutic value, commercial performance and R&D complexity.
By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose…
Read Now
